Literature DB >> 16831443

Monoclonal antibody classification based on epitope-binding using differential antigen disruption.

Ergang Shi1, Wen Fury, Wentian Li, Warren Mikulka, Thomas Aldrich, Ashique Rafique, Gang Chen, Simon Hoffenberg, Thomas J Daly, Czeslaw Radziejewski.   

Abstract

Currently, classifying a population of specific antigen-reactive monoclonal antibodies (mAbs) according to their epitope-binding properties has been limited to competition assays. Such assays are time consuming, labor intensive and restricted to the number of mAbs in the experiment. To overcome this problem, a differential antigen disruption-based antibody profiling procedure was developed. This procedure rapidly classifies specific antigen-reactive mAbs into epitope-related groups by measuring the binding signal of the antibodies to a set of structurally disrupted antigens and then clustering the antibodies according to the similarity of their binding profiles. The clustering results generated by differential antigen disruption showed a significant concordance with those generated by competition experiments. Therefore, differential antigen disruption method opens an opportunity to assess the entire population of antigen-reactive mAbs according to their epitope-binding properties. In doing so, a set of representative antibodies can be drawn to describe the epitope complexity for systematically exploring their functions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16831443     DOI: 10.1016/j.jim.2006.05.007

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  2 in total

Review 1.  Ion channels as therapeutic antibody targets.

Authors:  Catherine J Hutchings; Paul Colussi; Theodore G Clark
Journal:  MAbs       Date:  2018-12-10       Impact factor: 5.857

2.  The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025.

Authors:  Monireh Golpour; Pouya Vatanpour; Mina Amini; Majid Saeedi; Nasim Hafezi; Alireza Rafiei
Journal:  Adv Pharmacol Pharm Sci       Date:  2021-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.